BioStem Technologies (BSEM) to Release Earnings on Thursday

Key Points

• BioStem Technologies (OTCMKTS:BSEM) will release Q1 2026 earnings on Thursday, May 14, with analysts forecasting $0.04 EPS and $5.7M revenue; a conference call is scheduled for May 14 at 4:30 PM ET.
• The stock opened at $4.18, has a market capitalization of $71.02 million and a negative P/E of -9.86, with a one-year range of $3.09–$15.45 and 50/200-day moving averages near $4.95/$4.85.
• Coverage is limited but mixed: HC Wainwright started coverage with a Buy and a $9.00 target, Zacks rates it a Hold, and MarketBeat’s consensus is a Moderate Buy with an average $9.00 target.

BioStem Technologies (OTCMKTS:BSEM - Get Free Report) is expected to release its Q1 2026 resultson Thursday, May 14th. Analysts expect BioStem Technologies to post earnings of $0.04 per share and revenue of $5.70 million for the quarter. Interested persons can find conference call details on the company's upcoming Q1 2026 earning report page for the latest details on the call scheduled for Thursday, May 14, 2026 at 4:30 PM ET.

BioStem Technologies Price Performance

OTCMKTS BSEM opened at $4.18 on Thursday. The stock has a market capitalization of $71.02 million, a price-to-earnings ratio of -9.86 and a beta of 0.09. BioStem Technologies has a one year low of $3.09 and a one year high of $15.45. The business's fifty day moving average is $4.95 and its 200-day moving average is $4.85.

Analyst Upgrades and Downgrades

A number of research firms have recently commented on BSEM. Zacks Research upgraded BioStem Technologies to a "hold" rating in a research note on Wednesday, March 18th. HC Wainwright began coverage on BioStem Technologies in a research note on Wednesday. They set a "buy" rating and a $9.00 target price on the stock. One investment analyst has rated the stock with a Buy rating and one has issued a Hold rating to the company's stock. According to MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average target price of $9.00.

BioStem Technologies Company Profile

BioStem Technologies, Inc, a life sciences corporation, focuses on discovering, developing, and producing pharmaceutical and regenerative medicine products and services. It develops various biologic stem cell based alternative products, as a treatment for ailments, such as joint pain, tendon and ligament injuries, neurodegenerative, and autoimmune diseases. The company is also engages in the repackaging and distribution of active pharmaceutical ingredients and other pharmaceutical compounding supplies; and develops and markets nutraceutical products under the Dr.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.